RCM
AMPH icon

Raleigh Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Raleigh Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-159
Closed -$9.83K – 976
2023
Q4 		$9.83K Buy
159
+21
+15% +$1.1K ﹤0.01% 590
2023
Q3 		$6.35K Buy
138
+14
+11% +$764 ﹤0.01% 643
2023
Q2 		$7.13K Buy
+124
New +$5.5K ﹤0.01% 554

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Raleigh Capital Management's AMPH Position: Q1 2024 in Review

Raleigh Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2024, closing a stake of 159 shares — an estimated $9.83K sold.

Raleigh Capital Management first reported a position in AMPH in Q2 2023 and held it in 3 quarters. The position peaked at $9.83K in Q4 2023. 270 funds tracked by Wall St. Rank hold AMPH as of Q1 2024.

  • Raleigh Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Raleigh Capital Management sold 159 Amphastar Pharmaceuticals shares in Q1 2024, an estimated $9.83K.
  • Raleigh Capital Management first reported a position in Amphastar Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Raleigh Capital Management's Amphastar Pharmaceuticals position peaked at $9.83K in Q4 2023.
  • 270 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2024.

Based on Raleigh Capital Management's 13F filing for Q1 2024, filed 13 May 2024.